Medtronic D&A increased by 0.5% to $749.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 9.5%, from $684.00M to $749.00M. Over 3 years (FY 2022 to FY 2025), D&A shows relatively stable performance with a 1.9% CAGR.
Higher levels typically reflect significant historical capital expenditures or acquisitions that are now being expensed over time.
This metric represents the non-cash accounting charges used to allocate the cost of tangible assets and intangible asset...
Capital-intensive hardware manufacturers generally show higher D&A relative to revenue than pure-play software companies.
cf_depreciation_and_amortization| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $671.00M | $676.00M | $672.00M | $688.00M | $668.00M | $671.00M | $679.00M | $679.00M | $672.00M | $672.00M | $649.00M | $654.00M | $662.00M | $675.00M | $684.00M | $840.00M | $748.00M | $745.00M | $749.00M |
| QoQ Change | — | +0.7% | -0.6% | +2.4% | -2.9% | +0.4% | +1.2% | +0.0% | -1.0% | +0.0% | -3.4% | +0.8% | +1.2% | +2.0% | +1.3% | +22.8% | -11.0% | -0.4% | +0.5% |
| YoY Change | — | — | — | — | -0.4% | -0.7% | +1.0% | -1.3% | +0.6% | +0.1% | -4.4% | -3.7% | -1.5% | +0.4% | +5.4% | +28.4% | +13.0% | +10.4% | +9.5% |